<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/25/adamis-pharmaceuticals-nasdaqadmp-cut-to-hold-at-maxim-group.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-25T12:46:07+00:00"/>
    <meta property="og:title" content="Adamis Pharmaceuticals (NASDAQ:ADMP) Cut to Hold at Maxim Group"/>
    <meta property="og:description" content="Adamis Pharmaceuticals (NASDAQ:ADMP) was downgraded by investment analysts at Maxim Group from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, The Fly reports. ADMP has been the topic of several other reports. Zacks Investment Research raised shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” […]"/>
  </head>
  <body>
    <article>
      <h1>Adamis Pharmaceuticals (NASDAQ:ADMP) Cut to Hold at Maxim Group</h1>
      <address><time datetime="2019-11-25T12:46:07+00:00">25 Nov 2019, 12:46</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/adamis-pharmaceuticals-corp-logo.png"/>
      </figure>
      <p>Adamis Pharmaceuticals (NASDAQ:ADMP) was downgraded by investment analysts at Maxim Group from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, <a href="https://www.thefly.com/">The Fly</a> reports.</p>
      <p>ADMP has been the topic of several other reports. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> raised shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=ADMP">ValuEngine</a> raised shares of Adamis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. Adamis Pharmaceuticals presently has an average rating of “Buy” and an average target price of $3.09.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/ADMP/price-target/">ADMP</a> traded down $0.61 during trading on Monday, hitting $0.65. The company had a trading volume of 620,504 shares, compared to its average volume of 2,535,331. The company has a market capitalization of $65.95 million, a PE ratio of -0.65 and a beta of 1.38. Adamis Pharmaceuticals has a one year low of $0.48 and a one year high of $3.29. The firm’s 50-day moving average price is $0.75 and its 200 day moving average price is $1.10. The company has a quick ratio of 1.46, a current ratio of 1.69 and a debt-to-equity ratio of 0.04.</p>
      <p>Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $5.90 million during the quarter, compared to the consensus estimate of $6.55 million. Adamis Pharmaceuticals had a negative net margin of 175.77% and a negative return on equity of 90.00%. Sell-side analysts forecast that Adamis Pharmaceuticals will post -0.47 earnings per share for the current year.</p>
      <p>Large investors have recently modified their holdings of the business. Wedbush Securities Inc. lifted its position in Adamis Pharmaceuticals by 139.8% during the 2nd quarter. Wedbush Securities Inc. now owns 44,600 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 26,000 shares in the last quarter. A.R.T. Advisors LLC raised its holdings in shares of Adamis Pharmaceuticals by 143.8% in the 2nd quarter. A.R.T. Advisors LLC now owns 61,711 shares of the specialty pharmaceutical company’s stock valued at $80,000 after purchasing an additional 36,400 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Adamis Pharmaceuticals in the 2nd quarter valued at about $181,000. Morgan Stanley raised its holdings in shares of Adamis Pharmaceuticals by 189.7% in the 2nd quarter. Morgan Stanley now owns 757,124 shares of the specialty pharmaceutical company’s stock valued at $984,000 after purchasing an additional 495,793 shares during the period. Finally, BlackRock Inc. raised its holdings in shares of Adamis Pharmaceuticals by 1.5% in the 2nd quarter. BlackRock Inc. now owns 962,687 shares of the specialty pharmaceutical company’s stock valued at $1,252,000 after purchasing an additional 14,312 shares during the period. 11.88% of the stock is currently owned by hedge funds and other institutional investors.</p>
      <p>
        <b>Adamis Pharmaceuticals Company Profile</b>
      </p>
      <p>Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.</p>
      <p>Further Reading: <a href="https://www.marketbeat.com/financial-terms/certificate-of-deposit-risk-adverse-investors/">Understanding Specialty Certificates of Deposit</a></p>
      <figure>
        <img src="https://www.marketbeat.com/images/flyonthewall.png"/>
      </figure>
    </article>
  </body>
</html>